journal
MENU ▼
Read by QxMD icon Read
search

Clinical Neuropharmacology

journal
https://www.readbyqxmd.com/read/30398989/possible-sertraline-induced-hiccups-in-a-boy-with-obsessive-compulsive-disorder-and-attention-deficit-hyperactivity-disorder
#1
Ayhan Bilgiç
Hiccup is a sudden-onset repeated involuntary and spasmodic contraction of the diaphragm and intercostal muscle accompanied by laryngeal closure, generating the characteristic inspiratory sound and discomfort. Various factors including drugs may trigger the hiccups. There are some reports regarding the possible links between psychotropic agents that can affect the dopaminergic system and the triggering of hiccup; however, to our knowledge, there are no data regarding sertraline-induced hiccup. We present the case of a boy with obsessive-compulsive disorder and attention-deficit/hyperactivity disorder who displayed hiccup after sertraline therapy...
November 5, 2018: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/30303817/nighttime-sleep-and-daytime-sleepiness-improved-with-pimavanserin-during-treatment-of-parkinson-s-disease-psychosis
#2
Neepa Patel, Peter LeWitt, Ariel B Neikrug, Patrick Kesslak, Bruce Coate, Sonia Ancoli-Israel
INTRODUCTION: Impaired nocturnal sleep and excessive daytime sleepiness are common problems for patients with Parkinson's disease, and patients with Parkinson's disease with sleep dysfunction are 5 times more likely to experience psychotic symptoms. Pimavanserin, a 5-HT2A inverse agonist approved to treat Parkinson's disease psychosis, may improve sleep quality in patients with Parkinson's disease experiencing sleep disturbances. METHODS: Scales for Outcomes in Parkinson's Disease nighttime sleep (SCOPA-NS) and SCOPA-daytime sleepiness (DS) data obtained during 2 double-blind placebo-controlled studies of pimavanserin in persons with Parkinson's disease psychosis were evaluated...
October 9, 2018: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/30273192/increased-risk-of-ischemic-stroke-in-multiple-myeloma-associated-with-lenalidomide-treatment-a-case-report-and-review-of-the-literature
#3
Elena de Celis, María Alonso de Leciñana, Jorge Rodríguez-Pardo, Blanca Fuentes, Exuperio Díez-Tejedor
OBJECTIVE: The aim of the study was to illustrate the increased risk of ischemic stroke in the context of multiple myeloma (MM) under treatment with lenalidomide combined with dexamethasone. METHODS: This is a case report and literature review. RESULTS: A 62-year-old woman diagnosed with relapsed MM under treatment with lenalidomide and dexamethasone presented with acute onset disorientation, disturbed behavior, and aphasia. Cranial computed tomography scan revealed an acute cerebral infarction in the left middle cerebral artery territory, and brain magnetic resonance imaging showed additional silent ischemic lesions in other arterial territories...
September 28, 2018: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/30273191/fludarabine-induced-posterior-reversible-encephalopathy-syndrome-in-a-pediatric-patient-with-%C3%AE-thalassemia-case-report-and-literature-review
#4
Cristian Eduardo Navarro, Paula Juliana Rodríguez, Oscar Mauricio Espitia
Posterior reversible encephalopathy syndrome is a disorder of reversible subcortical vasogenic brain edema in the context of different diseases or exposure to cytotoxic drugs such as fludarabine. We present the case of a pediatric patient with β-thalassemia who develops a fludarabine-induced posterior reversible encephalopathy while he received an induction regimen to achieve an allogenic hematopoietic cell transplantation. The clinical presentation consists in altered mental state, headache, status epilepticus, visual disturbance, and hypertension...
September 28, 2018: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/30273190/adjunctive-donepezil-for-anxiety-symptoms-with-poor-response-to-paroxetine-in-a-patient-with-probable-mild-cognitive-impairment
#5
Ching-Wen Chu, Chih-Sung Liang, Fang-Jung Wan
No abstract text is available yet for this article.
September 28, 2018: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/30273189/urinary-retention-associated-with-cariprazine-a-case-report
#6
Leonid Kapulsky, Benjamin D Brody
Urinary retention is a well-documented adverse effect of antipsychotic medications and is thought to be mediated by anticholinergic, adrenergic, and other neurotransmitter effects. Whereas urinary retention has been reported with typical and some atypical antipsychotics, there have been no reports of urinary retention with the novel antipsychotic cariprazine. We report on a case of urinary retention associated with cariprazine. Possible mechanisms for this adverse effect are discussed.
September 28, 2018: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/30234559/levetiracetam-induced-seizure-aggravation-in-patients-with-focal-cortical-dysplasia
#7
Emilija Cvetkovska, Igor Kuzmanovski, Marija Babunovska, Bojan Boshkovski, Katina Aleksovska, Gordana Kiteva Trencevska
OBJECTIVES: The choice of antiepileptic drug is typically based on seizure type, and there is no evidence for superior effectiveness or potential deterioration of particular antiepileptic drug in specific etiologic subgroups. The aim of the study was to identify etiological factor(s) associated with increased risk of seizure aggravation with levetiracetam (LEV). METHODS: A retrospective analysis of 139 patients treated with LEV was performed. Seizure aggravation was defined as a 100% or greater increase in seizures frequency, which occurred within 1 month of drug introduction...
September 18, 2018: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/30234558/natalizumab-treatment-for-relapsing-remitting-multiple-sclerosis-the-experience-from-saudi-arabia
#8
Hussein Algahtani, Bader Shirah, Hind Abobaker, Nebras Alghanaim, Fatemah Kamel
BACKGROUND: Natalizumab is the first targeted humanized monoclonal antibody to be approved for the treatment of relapsing-remitting multiple sclerosis (RRMS). Natalizumab appears to be more effective than current first-line disease-modifying therapies. In our study, we aimed to evaluate the outcome of Saudi patients with active RRMS treated with natalizumab and compare the results with other outcomes in the Gulf and international trials. METHODS: We conducted a retrospective single-center observational study involving 32 patients with RRMS at King Abdulaziz Medical City in Jeddah, Saudi Arabia...
September 18, 2018: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/30204599/tandospirone-induced-rhabdomyolysis
#9
Kensuke Miyazaki, Masabumi Otaka, Norio Yasui-Furukori
BACKGROUND: Rhabdomyolysis involves the release of intracellular contents secondary to muscle cell injury; it generally presents with muscle pain and weakness. Although several psychotropic agents have been documented as causes of rhabdomyolysis, there are no reports of tandospirone-induced rhabdomyolysis. CASE: We present the case of a 15-year-old Japanese girl who had posttraumatic stress disorder after the Great East Japan Earthquake. She received a dose of 60 mg of tandospirone while taking 10 mg of tandospirone and 400 mg of valproic acid every day...
September 10, 2018: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/30204598/a-case-of-musical-hallucinations-related-to-mirtazapine
#10
Grace H Lee, Jonathan T Stewart
Musical hallucinations (MHs) are relatively uncommon phenomena sometimes encountered in older patients, especially older women. They usually involve popular, overlearned music, either entire songs or repetitive snippets. While MHs are most commonly associated with hearing loss, they may occur in a variety of psychiatric, neurologic, and iatrogenic conditions. We report a 91-year-old man whose MHs were causally related to the antidepressant mirtazapine. Although mirtazapine is generally well tolerated, it may rarely cause MHs or other psychotic symptoms...
September 10, 2018: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/30130259/treatment-of-myasthenia-gravis-with-high-dose-cholinesterase-inhibitors-and-calcineurin-inhibitors-caused-spontaneous-muscle-cramps-in-patients
#11
Masayuki Masuda, Hiroya Utsumi, Sachiko Tanaka, Akemi Maeno, Mamiko Yamamoto, Kentaro Sugiyama, Toshihiko Hirano, Hitoshi Aizawa
OBJECTIVES: The objective of this study was to investigate the influence of treatment with cholinesterase inhibitors (ChEIs) and calcineurin inhibitors (CNIs) on the occurrence of cramps in myasthenia gravis (MG) patients. METHODS: The frequency and duration of cramp and serum electrolytes were evaluated in 81 patients with MG. The patients were classified using Myasthenia Gravis Foundation of America postintervention status scores based on the treatment and the responsiveness to the treatment...
August 20, 2018: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/30234617/movement-disorders-after-exposure-to-antipsychotic-drugs-in-patients-with-depressive-disorders
#12
María Verónica Rey, Luis Molina, Byron Recinos, Bezner Paz, Mauricio Rovelo, Fanny Elizabeth Rodriguez Elias, José Calderón, Arturo Arellano, Santiago Perez-Lloret
OBJECTIVES: The aims of the study were to explore the frequency of movement disorders (MDs) in depressive patients exposed to antipsychotic drugs (APDs) and to compare it with nonexposed depressive patients and APDs-treated schizophrenic patients. METHODS: Four hundred fifty-two depressive patients not exposed to APDs (group A), 156 depressives exposed to APDs (group B), and 75 patients with schizophrenia on APDs (group C) were recruited. Presence of MDs was explored by the Simpson-Angus and UKU scales (Registration: NCT02409823)...
September 2018: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/30234616/clostridium-butyricum-miyairi-588-as-adjunctive-therapy-for-treatment-resistant-major-depressive-disorder-a-prospective-open-label-trial
#13
Tsuyoshi Miyaoka, Misako Kanayama, Rei Wake, Sadayuki Hashioka, Maiko Hayashida, Michiharu Nagahama, Shihoh Okazaki, Satoko Yamashita, Shoko Miura, Hiroyuki Miki, Hiroyuki Matsuda, Masahiro Koike, Muneto Izuhara, Tomoko Araki, Keiko Tsuchie, Ilhamuddin Abdul Azis, Ryosuke Arauchi, Rostia Arianna Abdullah, Arata Oh-Nishi, Jun Horiguchi
AIM: Up to 60% of depressed patients do not obtain sufficient relief from a course of antidepressant therapy, and these treatment-resistant major depressive disorder (TRD) patients are at increased risk for relapse, chronicity, persistent psychosocial impairments, and suicide. Probiotics actively participate in treatment of neuropsychiatric disorders. However, the role of gut microbiota in brain disorders and depression remains unclear. We performed a prospective study to evaluate the effects of Clostridium butyricum MIYAIRI 588 (CBM588)...
September 2018: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/30036197/efficacy-and-safety-of-atypical-antipsychotics-in-bipolar-disorder-with-comorbid-substance-dependence-a-systematic-review
#14
Gianna Sepede, Marco Lorusso, Maria Chiara Spano, Piero Di Nanno, Giuseppe Di Iorio, Massimo Di Giannantonio
OBJECTIVES: Bipolar disorder (BD) patients with a comorbid substance use disorder (SUD) are notoriously difficult to treat. Atypical antipsychotics (AAPs) are widely prescribed in BD, but their efficacy in patients with comorbid SUD is still debated. The aim of the present article is to systematically review the literature findings on the efficacy and safety of AAPs in BD patients with comorbid SUD. METHODS: We searched PubMed to identify original studies focused on the treatment of dual diagnosed BD with AAPs...
September 2018: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/30024443/tetrahydrocannabinol-cannabidiol-oromucosal-spray-in-patients-with-multiple-sclerosis-a-pilot-study-on-the-plasma-concentration-effect-relationship
#15
Manuela Contin, Luca Mancinelli, Alessandro Perrone, Loredana Sabattini, Susan Mohamed, Cinzia Scandellari, Matteo Foschi, Veria Vacchiano, Alessandra Lugaresi, Roberto Riva
OBJECTIVES: We aimed to assess the potential relationship between intrasubject 9-tetrahydrocannabinol/cannabidiol (THC/CBD) oromucosal spray plasma profiles and clinical effects elicited by subacute dosing in chronically treated patients with multiple sclerosis (MS). METHODS: The study design was pilot, single center, open, and prospective. The patients were challenged with a morning test dose of 2 THC/CBD sprays at a 15-minute interval. Venous blood samples were collected before the first spray administration and every 30 minutes after the second spray, until 240 minutes postdosing...
July 18, 2018: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/30024442/fluoxetine-induced-skin-picking-and-compulsive-behaviors-in-a-preschool-girl
#16
Fatma Çoşkun, Ayhan Bilgiç
Skin-picking disorder is regarded as a type of obsessive-compulsive and related disorders according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Selective serotonin reuptake inhibitors (SSRIs) are reported to be effective in the treatment of skin-picking disorder. However, these agents can cause opposite effects in some cases. There is a report on SSRI-induced skin-picking disorder in adults. However, to our knowledge, there are no data regarding SSRI-induced skin picking in children...
July 18, 2018: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/30024441/efficacy-of-parenteral-amantadine-therapy-in-the-treatment-of-multiple-system-atrophy-with-predominant-parkinsonism
#17
Adit Friedberg, Ilana Erikh, Maria Nassar, Elliot Sprecher, Ilana Schlesinger
OBJECTIVE: The aim of this study was to assess clinical response to a high-dose intravenous (IV) amantadine given for 5 consecutive days in patients with multiple system atrophy parkinsonism (MSA-P). METHODS: Subjects with a diagnosis of MSA-P treated with IV amantadine were included. Patients' disease severity before and after therapy was evaluated using the Unified Multiple System Atrophy Rating Scale (UMSARS). RESULTS: Fourteen subjects (8 females) were included...
July 18, 2018: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/30004964/pimavanserin-for-psychotic-symptoms-in-people-with-parkinsonism-a-second-chart-review
#18
Joseph H Friedman
INTRODUCTION: Pimavanserin (Pim) is a 5HT2A inverse agonist that is the only Food and Drug Administration-approved treatment for Parkinson disease (PD) psychosis. The published open-label experience is limited. METHODS: This report is a chart review of all patients who were started on the drugs since the one earlier report on 15 patients. All patients were included, whether or not they completed 6 weeks of treatment, the time required for maximum benefit found in the published phase 3 trial...
July 13, 2018: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/29979192/fluoxetine-induced-sleep-bruxism-rapidly-treated-with-once-nightly-dosing-of-buspirone-in-a-6-year-old-girl
#19
Betül Akbaş, Ayhan Bilgiç
Fluoxetine is a selective serotonin reuptake inhibitor that is commonly used in children and adolescents. Several reports exist regarding the relationship of fluoxetine use and sleep bruxism. We report the case of a 6-year-old girl who was successfully treated with once-nightly dosing of buspirone for fluoxetine-induced sleep bruxism, which was confirmed with clear on-off-on treatment sequence.
July 3, 2018: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/30001249/successful-intrathecal-baclofen-therapy-for-intractable-paroxysmal-sympathetic-hyperactivity-in-patient-with-pontine-hemorrhage-a-case-report
#20
Hyeon Su Kim, Na Young Kim, Yong Wook Kim
Paroxysmal sympathetic hyperactivity (PSH) is characterized by increased activity of the sympathetic nervous system. Although several treatments have been proposed for PSH, their efficacies are uncertain. We report a case of a patient with intractable PSH after pontine hemorrhage who was treated with intrathecal baclofen (ITB). A 61-year-old man was diagnosed with pontine hemorrhage expanding to the bilateral midbrain. Beginning 2 weeks after onset, he developed paroxysmal hyperthermia, tachycardia, tachypnea, hypertension, and generalized dystonic movements...
July 2018: Clinical Neuropharmacology
journal
journal
26752
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"